Braveheart Bio

Develops therapies for hypertrophic cardiomyopathy and cardiovascular disease.

BiotechnologyPharmaceuticals

Company facts

Founded
2025
Employees
40
Headquarters
United States
Type
Private
Funding
Series A · $185M · 2025